Free tool
FAERS Monitor: Ec-Naprosyn
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020067 or its brand name (Ec-Naprosyn, Naproxen). Reports on generic versions are filed under their own applications.
Reports
79,146
Serious
63,169
80% of reports
Hospitalization
26,492
Death reported
8,212
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective10,286
- pain9,130
- fatigue7,750
- arthralgia7,621
- nausea7,479
- off label use6,467
- headache6,074
- diarrhoea5,719
- vomiting5,077
- dizziness5,063
- rash4,946
- dyspnoea4,900
- malaise4,706
- joint swelling4,599
- rheumatoid arthritis4,563
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 709 |
| 2005 | 825 |
| 2006 | 810 |
| 2007 | 781 |
| 2008 | 959 |
| 2009 | 1,157 |
| 2010 | 1,448 |
| 2011 | 2,024 |
| 2012 | 2,634 |
| 2013 | 2,544 |
| 2014 | 2,845 |
| 2015 | 3,986 |
| 2016 | 4,944 |
| 2017 | 4,276 |
| 2018 | 5,510 |
| 2019 | 6,942 |
| 2020 | 7,152 |
| 2021 | 5,774 |
| 2022 | 4,858 |
| 2023 | 5,171 |
| 2024 | 5,377 |
| 2025 | 5,370 |
| 2026 | 3,050 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,975,013 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rheumatoid arthritisSignal | 4,563 | 11.1 | 10.8 | 40,398 |
| joint swellingSignal | 4,599 | 10.5 | 10.2 | 38,173 |
| arthralgiaSignal | 7,621 | 4.9 | 4.8 | 24,003 |
| painSignal | 9,130 | 4.0 | 3.9 | 20,794 |
| rashSignal | 4,946 | 3.0 | 3.0 | 6,827 |
| vomitingSignal | 5,077 | 2.9 | 2.8 | 6,348 |
| malaiseSignal | 4,706 | 2.9 | 2.8 | 5,798 |
| dizzinessSignal | 5,063 | 2.7 | 2.6 | 5,559 |
| fatigueSignal | 7,750 | 2.7 | 2.6 | 8,265 |
| headacheSignal | 6,074 | 2.6 | 2.5 | 6,050 |
| nauseaSignal | 7,479 | 2.5 | 2.5 | 7,093 |
| diarrhoeaSignal | 5,719 | 2.4 | 2.3 | 4,613 |
| dyspnoeaSignal | 4,900 | 2.3 | 2.2 | 3,714 |
| drug ineffectiveSignal | 10,286 | 2.1 | 2.0 | 6,126 |
| off label use | 6,467 | 2.0 | 1.9 | 3,197 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.